{"entity":{"id":"nct05768919","kind":"trial","name":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","aka":[],"tldr":"A phase 1/2 trial of Treatment Period 1 in glioma & glioblastoma, run by SignPath Pharma, Inc., now recruiting.","summary":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas is a phase 1/2 interventional study registered as NCT05768919 by SignPath Pharma, Inc., with 30 participants planned, started 2023-03-03 and due to reach its primary completion in 2026-02. Interventions recorded: Treatment Period 1, Treatment Period 2, Treatment Period 3 and Treatment Period 4a.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05768919","url":"https://clinicaltrials.gov/study/NCT05768919"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05768919","phase":"1/2","setting":"Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas","sponsor":"SignPath Pharma, Inc.","started":"2023-03-03","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05768919/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}